Other
Neoadjuvant Treatment
0
Pipeline Programs↗
25
Active Trials↗
6
Companies Involved↗
Neoadjuvant Treatment is an early-stage landscape with 0 programs across 6 companies. The most active players are Eli Lilly, Innovent Biologics (Suzhou) Co. Ltd., Tanvex BioPharma USA, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
64
clinical trials
Completed20 · 31%
Recruiting16 · 25%
Unknown status15 · 23%
Not yet recruiting7 · 11%
Active, not recruiting2 · 3%
Terminated2 · 3%
Other2 · 3%
Clinical Trials
Trial Activity
64 trials
XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer
Recruiting·—·Phase 2·NCT05815303·92 enrolled
Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC
Recruiting·—·N/A·NCT05974007·1,500 enrolled
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Recruiting·—·Phase 3·NCT06102395·272 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)